Sino Biopharmaceutical (01177) to Acquire 95.09% Stake in LaNova Medicines

Stock Track
07/15

Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest in LaNova Medicines. The transaction carries a maximum consideration of approximately US$951 million. After deducting LaNova's estimated cash and bank deposits of US$450 million at closing, the net payment required from the buyer amounts to roughly US$501 million.

Currently, the acquiring subsidiary holds a 4.91% stake in LaNova Medicines. Upon completion of the acquisition, Sino Biopharmaceutical will own 100% of LaNova, making it an indirect wholly-owned subsidiary.

LaNova Medicines represents a globally leading innovative drug R&D company specializing in tumor immunology and tumor microenvironment research. This strategic move substantially aligns with Sino Biopharmaceutical's innovation-driven and internationalization strategy. The acquisition is expected to significantly enhance the group's core competitiveness and global influence within the oncology innovation sector.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10